Clinical trial · Interventional
Repeatability of Positron Emission Tomography (TEP) With fluorométhyl-(18F)-diméthyl-2-hydroxyéthyl-ammonium
NCT03105869CI-TRIAL-00028258completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Monocentric study. Objective : Determination of the repeatability of fluorocholine PET/CT in prostate cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| fluorocholine PET/CT | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- fluorocholine PET/CT
- description
- all patients will undergo a second PET/CT with fluorocholine
- interventionNames
- Diagnostic Test: fluorocholine PET/CT
Primary outcomes (1)
- measure
- reproducibility of the results
- timeFrame
- 2 weeks
- description
- Comparison of the number and location of identified lesions and comparison of lesion uptake
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion criteria : * biological suspicion of relapse of prostate cancer or initial staging of prostate cancer * positive PET/CT with fluororocholine Exclusion criteria : -none
References
Publications (0)
Data not yet available
No reference posted for this study.